Dhaka, May 8, 2025—In a landmark move to strengthen access to affordable and quality medicines, improve public health, and support economic growth, IFC committed a $58 million long-term loan to Renata PLC, a leading pharmaceutical company in Bangladesh. This financing will help address the company’s critical working capital needs, offering essential liquidity support amid limited U.S. dollar financing availability. IFC aims to bolster the country’s pharmaceutical sector and its capacity to deliver essential healthcare products.
Bangladesh's pharmaceutical industry is rapidly growing, meeting 98% of local demand and expanding its global footprint. However, reliance on imported Active Pharmaceutical Ingredients (API) can present challenges. IFC’s investment will help Renata secure these materials, enhancing the industry’s ability to provide uninterrupted access to critical medicines.
Syed S Kaiser Kabir, CEO & Managing Director of Renata PLC said, “In the context of USD liquidity constraints, the ongoing risk of further devaluation of BDT vs USD and the ever-increasing cost of financing in Bangladesh, the IFC commitment to Renata will bring significant stability to our supply chain and support cost-effective manufacturing.”
The sector is a key driver of Bangladesh’s economy, with growing contributions through exports and skilled employment.
Imad N. Fakhoury, IFC Regional Director for South Asia said, "IFC’s partnership with Renata will drive crucial growth and create jobs in Bangladesh’s pharmaceutical industry. By supporting Renata's operations, we aim to help them maintain a robust supply chain and develop and register new products in international markets to ensure the availability of essential medicines. The partnership will bolster the competitiveness of Bangladesh’s pharmaceutical sector and solidify the country's standing in the international generics industry.”
IFC is committed to supporting private sector growth in Bangladesh, particularly in sectors critical to health, employment, and exports. This partnership with Renata reflects IFC’s strategic goal of driving sustainable growth and expanding Bangladesh’s impact in global markets.
About IFC
IFC — a member of the World Bank Group — is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2024, IFC committed a record $56 billion to private companies and financial institutions in developing countries, leveraging private sector solutions and mobilizing private capital to create a world free of poverty on a livable planet. For more information, visit www.ifc.org.
Stay Connected with IFC on social media.
About Renata
Renata PLC is a public limited company incorporated in Bangladesh in 1972 as Pfizer Laboratories (Bangladesh) Limited under the Companies Act, 1913 and subsequently duly registered under Companies Act, 1994. The Company was listed with Dhaka Stock Exchange Limited on 12 May 1979. Subsequently, the Company was renamed as Renata Limited in 1993. Renata PLC is the only pharmaceutical with majority shareholding (51%) held by Sajida Foundation, a leading NGO in Bangladesh, reinforcing our strong commitment to social welfare.
The company along with its two subsidiaries (Renata (UK) Limited and Renata Pharmaceuticals (Ireland) Limited) is one of the leading pharmaceuticals in Bangladesh. The main activities of the company and its subsidiaries are manufacturing, marketing and distribution of pharmaceutical, animal health products, oncology-based products, agro-based products, poultry products and consumer products.
Renata has a fast-growing footprint across the world driving significant growth in exports underpinned by key strategic global partnerships and a portfolio of high-quality products including 78 bioequivalent products. As of today, we've successfully registered 420 SKUs across 59 countries worldwide, including some of the most highly regulated markets such as USA, Germany, Canada, UK, Singapore, Australia, Ireland, Denmark, Spain, France, Italy, Netherlands, Norway, Portugal, Sweden etc. Notably, in 2024 alone, we've secured approvals for 28 SKUs from 17 of these regulated countries, reflecting the growing global confidence in our high-quality products.
For more information, visit https://renata-ltd.com or follow us on Facebook and LinkedIn.
Sign up to have customizable news & updates sent to you.